Diverse metabolic response of cancer cells treated with a (213)Bi-anti-EGFR-immunoconjugate

Evaluation of treatment response is among the major challenges in modern oncology. We herein used a monoclonal antibody targeting the EGF receptor (EGFR) labelled with the alpha emitter (213)Bi ((213)Bi-anti-EGFR-MAb). EJ28Luc (bladder) and LN18 (glioma) cancer cells, both overexpressing EGFR, were...

Descripción completa

Detalles Bibliográficos
Autores principales: Feuerecker, Benedikt, Biechl, Philipp, Seidl, Christof, Bruchertseifer, Frank, Morgenstern, Alfred, Schwaiger, Markus, Eisenreich, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973706/
https://www.ncbi.nlm.nih.gov/pubmed/33737524
http://dx.doi.org/10.1038/s41598-021-84421-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973706/
https://www.ncbi.nlm.nih.gov/pubmed/33737524
http://dx.doi.org/10.1038/s41598-021-84421-4

Ejemplares similares